Notes
2017 US dollars
Reference
Mac S, et al. Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. Pediatrics 143: No. 5, May 2019. Available from: URL: http://doi.org/10.1542/peds.2018-4064
Rights and permissions
About this article
Cite this article
Palivizumab cost effective for RSV prophylaxis in targeted infants. PharmacoEcon Outcomes News 828, 24 (2019). https://doi.org/10.1007/s40274-019-5898-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5898-2